Results 81 to 90 of about 1,941 (170)
Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors
Wolfgang Siess +2 more
doaj +1 more source
ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.
Steven M. Bair +11 more
wiley +1 more source
This study characterized biofilm‐forming bacterial strains Pseudomonas aeruginosa MD3 and Bacillus toyonensis LD07 immobilized on sugarcane bagasse. This highly porous bio‐product demonstrated exceptional phenotypic plasticity and robust bioremediation efficacy, achieving 99% chlorpyrifos degradation at 4500 ppm.
Le Thi Nhi‐Cong +6 more
wiley +1 more source
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
Jialei Qi +12 more
openaire +2 more sources
Economic Burden of Chronic Lymphocytic Leukaemia in Australia
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao +4 more
wiley +1 more source
A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors
Phillip LR. Nicolson +5 more
doaj +1 more source
ABSTRACT Proliferative Kidney Disease (PKD) is a severe parasitic disease of salmonids caused by the malacosporean endoparasite Tetracapsuloides bryosalmonae. In the fish intermediate host, the parasite is disseminated via the circulatory system and ultimately reaches the kidney, where it matures before releasing infective spores into the environment ...
Céline Möckli +4 more
wiley +1 more source
A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of ...
Laura Airas +8 more
doaj +1 more source
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
BTK (Bruton’s tyrosine kinase) has become a key therapeutic target across several hematologic diseases, beginning with its original use in CLL/SLL.
Andrea Duminuco +9 more
doaj +1 more source

